Comparison of carbetocin with other uterotonic agents in preventing postpartum hemorrhage

Belinda Carlisa

doi:10.18203/2320-1770.ijrcog20184997

Authors

Belinda Carlisa Department of Obstetrics and Gynecology, Mauponggo Public Health Center, Nagekeo District, East Nusa Tenggara, Indonesia

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20184997

Keywords:

Carbetocin, Postpartum hemorrhage, Uterotonic agents

Abstract

Postpartum hemorrhage (PPH) is defined as blood loss of at least 500 ml or more after vaginal delivery and 1000 ml or more after abdominal delivery. It contributes up to 28% of maternal mortality worldwide and 30.3% of maternal death in Indonesia. 70% cases of PPH are caused by uterine atony. PPH can be prevented by doing routine use of uterotonic agents in active management of third stage of labour. Uterotonic agents that currently available are oxytocin, carbetocin, methylergometrine, syntometrine, misoprostol and carboprost. Carbetocin (a long-acting synthetic analogue of oxytocin) is a new drug which has stronger ability to induce uterine contraction than oxytocin. It does not induce hypertension like methylergometrine and syntometrine. Therefore, carbetocin can be considered as an alternative drug to oxytocin in women with severe preeclampsia. However, more studies are needed to assess the efficacy and safety of carbetocin for prevention of PPH in preeclamptic women. Compared to methylergometrine and syntometrine, carbetocin is more effective in reducing postpartum blood loss. Adverse effects like nausea and vomiting were lower in women treated with carbetocin. Compared to misoprostol, carbetocin is also superior in reducing blood loss. Adverse effects like shivering, fever and metallic taste were higher in women treated with misoprostol. Further studies are needed to assess the superiority between carbetocin and carboprost since there is no published literature yet regarding this topic. In conclusion, carbetocin is superior to other uterotonic agents in preventing postpartum hemorrhage with fewer adverse effects.

Metrics

Metrics Loading ...

References

Seow KM, Chen KH, Wang PH, Lin YH, Hwang JL. Carbetocin versus oxytocin for prevention of postpartum hemorrhage in infertile women with twin pregnancy undergoing elective cesarean delivery. Taiwan J Obstet Gynecol. 2017;56(3):273-5.

Kemenkes RI [Ministry of Health, Republic of Indonesia]. Pusat Data dan Informasi [Center of Data and Information]. 2014.

Leduc D, Senikas V, Lalonde AB, Ballerman C, Biringer A, Delaney M, et al. Active Management of the Third Stage of Labour: Prevention and Treatment of Postpartum Hemorrhage. J Obstet Gynaecol Canada. 2009;31(10):980-93.

World Health Organization. WHO recommendations for the prevention and treatment of postpartum haemorrhage. Geneva, Switzerland: WHO Press; 2012. Available at: http://apps.who.int/iris/bitstream/10665/75411/1/9789241548502_eng.pdf.

Gizzo S, Patrelli TS, Gangi S Di, Carrozzini M, Saccardi C, Zambon A, et al. Which uterotonic is better to prevent the postpartum hemorrhage? Latest news in terms of clinical efficacy, side effects, and contraindications: A systematic review. Reprod Sci. 2013;20(9):1011-9.

Alwani M, Singh S, Thakur R, Mishra S. A randomized study comparing rectally administered misoprostol after spinal anesthesia versus intramuscular oxytocin for prevention of postpartum hemorrhage in caesarean section. Int J Reprod Contraception, Obstet Gynecol. 2014;33(3):512-5.

Elbohoty AEH, Mohammed WE, Sweed M, Bahaa Eldin AM, Nabhan A, Abd-El-Maeboud KHI. Randomized controlled trial comparing carbetocin, misoprostol, and oxytocin for the prevention of postpartum hemorrhage following an elective cesarean delivery. Int J Gynecol Obstet. 2016;134(3):324-8.

Samimi M, Imani-Harsini A, Abedzadeh-Kalahroudi M. Carbetocin vs. syntometrine in prevention of postpartum hemorrhage: a double blind randomized control trial. Iran Red Crescent Med J. 2013;15(9):817-22.

Bai J, Sun Q, Zhai H. A comparison of oxytocin and carboprost tromethamine in the prevention of postpartum hemorrhage in high-risk patients undergoing cesarean delivery. Exp Ther Med. 2014;7(1):46-50.

Attilakos G, Psaroudakis D, Ash J, Buchanan R, Winter C, Donald F, et al. Carbetocin versus oxytocin for the prevention of postpartum haemorrhage following caesarean section: The results of a double-blind randomised trial. BJOG An Int J Obstet Gynaecol. 2010;117(8):929-36.

Maged AM, Hassan AM, Shehata NA. Carbetocin versus oxytocin for prevention of postpartum hemorrhage after vaginal delivery in high risk women. J Matern Neonatal Med. 2015;29(4):532-6.

Reyes OA, Gonzalez GM. Carbetocin versus oxytocin for prevention of postpartum hemorrhage in patients with severe preeclampsia: a double-blind randomized controlled trial. J Obstet Gynaecol Canada. 2011;33(11):1099-104.

Nucci B, Aya AGM, Aubry E, Ripart J. Carbetocin for prevention of postcesarean hemorrhage in women with severe preeclampsia: a before-after cohort comparison with oxytocin. J Clin Anesth. 2016;35:321-5.

Aziz S, Kazi S, Haq G, Soomro N. Oral misoprostol versus intramuscular oxytocin in the active management of the third stage of labour. J Pak Med Assoc. 2014;64(4):428-32.

Ali AEAE, Nasr AAM, Ahmed HH, Rasheedy MIE, Badawy M, Nasr AAM. Carbetocin versus Oxytocin and Misoprostol in prevention of atonic post-partum hemorrhage in high risk patients planed for cesarean delivery. Int J Reprod Contracept Obstet Gynecol. 2018;7(1):10-4.

Ramya KS, Shivanna S, Gopal N. Intravenous methergin versus intramuscular oxytocin in active management of third stage labour. Int J Recent Trends Sci Technol. 2015;14:260-4.

Mohamed HF, Mustafa GF, Ibrahim MA, Stefanos GE. Comparative study between intravenous bolus dose of carbetocin versus oxytocin during cesarean delivery in healthy parturients on blood loss: a randomized control trial. Med J Cairo Univ. 2015;83(2):167-72.

Rath W. Prevention of postpartum haemorrhage with the oxytocin analogue carbetocin. Eur J Obstet Gynecol Reprod Biol. 2009;147(1):15-20.

Government of South Australia. Ergot derivatives: prophylaxis for third stage management and postpartum haemorrhage. South Aust Perinat Pract Guidelines. 2016. Available at: http://www.sahealth.sa.gov.au/wps/wcm/connect/public+content/sa+health+internet/resources/policies/ergot+derivatives+prophylaxis+for+third+stage+management+and+postpartum+haemorrhage+-+sa+perinatal+practice+guidelines.

Government of South Australia. Clinical Guideline Prostaglandin Analogues for Major Postpartum Haemorrhage. South Aust Perinat Pract Guidelines. 2016. Available at: http://www.sahealth.sa.gov.au/wps/wcm/connect/public+content/sa+health+internet/resources/policies/prostaglandin+analogues+for+postpartum+haemorrhage+-+perinatal+practice+guidelines.

Hassan FI, Ahmad AA, Khaled MM, Diwer YM. Comparative study between carbetocin versus oxytocin in prevention of post-partum haemorrhage following caesarean section in high-risk pregnancies. Med J Cairo Univ. 2017;85(4):1469-75.

Taheripanah R, Shoman A, Karimzadeh M, Zamaniyan M, Malih N. Efficacy of oxytocin versus carbetocin in prevention of postpartum hemorrhage after cesarean section under general anesthesia: a prospective randomized clinical trial. J Matern Fetal Neonatal Med. 2018;31(21):2807-12.

Khalafalah MM. Oxytocin vs carbetocin in management of 3rd stage at risk of PPH. MOJ Women’s Heal. 2017;5(4):5.

Boonkoonchanok Y, Suthutvoravut S. Comparison of postpartum blood loss between intravenous carbetocin and intravenous methylergometrine maleate administered immediately at the third stage of labor. Ramathibodi Med J. 2017;40:1-7.

Askar AA, Ismail MT, Abo El-Ezz A, Rabie NH. Carbetocin versus syntometrine in the management of third stage of labor following vaginal delivery. Arch Gynecol Obstet. 2011;284(6):1359-65.

Mohamed Maged A, Ragab AS, Elnassery N, Ai Mostafa W, Dahab S, Kotb A. Carbetocin versus syntometrine for prevention of postpartum hemorrhage after cesarean section. J Matern Neonatal Med. 2016;30(8):962-6.

Ibrahim KAAM, Saad AS. Prevention of postpartum haemorrhage in patients with severe preeclampsia using carbetocin versus misoprostol. Apollo Med. 2017;14(2):117-22.